|
||||||||||||||||||||||
|
|
Pilot Phase II Chemotherapy with IPP plus N-Acetylcysteine for Refractory Testicular Cancer
Basic Trial Information
Objectives I. Determine the objective response and duration of response in patients with testicular cancer refractory to cis-platinum combinations who are treated with ifosfamide, with N-acetylcysteine for bladder protection. II. Determine the toxicity of high-dose ifosfamide in patients with refractory testicular cancer. Entry Criteria Disease Characteristics: See General Eligibility Criteria Patient Characteristics: See General Eligibility Criteria General Eligibility Criteria: Patients with a tissue diagnosis of testicular cancer who have clearly measurable and progressive disease. Patients must have previously been treated with cis-platinum, vinblastine, bleomycin, and VP-16 and must be clearly refractory to these agents. The serum creatinine may not be greater than 3.0 mg/dl, and the creatinine clearance must be at least 50 mg/ml. Expected Enrollment Protocol closed February 1984. Outline Nonrandomized study. Single-agent Chemotherapy. Ifosfamide, IPP, NSC-109724; plus N-Acetylcysteine for bladder protection.Published Results Wheeler BM, Loehrer PJ, Williams SD, et al.: Ifosfamide in refractory male germ cell tumors. J Clin Oncol 4 (1): 28-34, 1986.[PUBMED Abstract] Trial Lead Organizations Indiana University Melvin and Bren Simon Cancer Center
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |